European Association of Urology 27th Meeting of the EAU Section of Urological Research 2021
Format:5 videos + 1 pdf, size: 26.7 GB
Course Audience: urology physician
Day 1 Room 1 (Video MP4 Format)
Day 1 Room 2 (Video MP4 Format)Day 2 Room 1 (Video MP4 Format)Day 2 Room 2 Part 1 (Video MP4 Format)Day 2 Room 2 Part 2 (Video MP4 Format)ESUR21 – 27th Meeting of the EAU Section of Urological Research (PDF Format)
***Detail:
Friday 8 October 2021
12:00 – 12:02 Welcome – Chairs K. Junker, Homburg (DE) G. Van Der Pluijm, Leiden (NL)12:02 – 12:40 Session 1: Patient-derived and Humanized Models for Translational Cancer Research – Chairs G. Van Der Pluijm, Leiden (NL) H.Y. Leung, Glasgow (GB)12:02 – 12:20 Humanized PDX models of immuno-oncology – R. Gareus, (DE)12:20 – 12:40 GPS for biology; imaging and profiling of FFPE fixed tissue samples – D. Mustafa, Rotterdam (NL)12:40 – 13:20 EAU Research Foundation: Awardees12:40 – 12:50 Introduction – G. Jenster, Rotterdam (NL)12:50 – 13:05 2018 Establishment Penile Cancer Patient-derived Xenograft in Nude Urologist – M. Albersen, Leuven (BE)13:05 – 13:20 Role of primary tumor in metastatic prostate cancer mouse model Urologist – J. Linxweiler, Homburg/saar (DE)13:20 – 13:50 Presentations selected from abstracts 1 – Chairs G. Van Der Pluijm, Leiden (NL) H.Y. Leung, Glasgow (GB)O07 Development of novel prostate cancer patient-derived models and applications for translational research – R. Servant, Basel (CH)O09 Mutant reovirus with oncolytic and immune-modulatory effects in human and murine prostate cancer models – T.J.A. Janssen, Leiden (NL)O02 Adrenal glands promote sclerotic progression of castration resistant prostate cancer in vivo – M. Hagberg Thulin, Gothenburg (SE)14:10 – 15:10 Poster Session 1 – Chairs K.A. Tasken, Oslo (NO) I. Ahmad, Glasgow (GB)P12 Influence of patient-derived fibroblasts on prostate cancer tumorigenesis in-vitro – A. Tagat, Homburg (DE)P16 The in vitro activity of Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma – A. Zaccagnino, Homburg/Saar (DE)P20 Testicular disorders’ awareness and knowledge among Portuguese high-school students Urologist – R. Catarino, Maia (PT)P24 Integrating analysis of the expression of IDO1 and TDO2 in bladder cancer Pathologist – T. Nguyen, Ho Chi Minh (VN)P27 Urinary retention as prognostic factor of short-term response to treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)14:25 – 14:30 DiscussionP09 Study of the effect of Erythropoietin on the kidney graft quality; an experimental animal model for kidney grafts preservation before transplantation Urologist – Z. Kratiras, Agria – Volos (GR)P08 Study of the effect of Sildenafil on the kidney graft quality; an experimental animal model for kidney grafts preservation before transplantation Urologist – Z. Kratiras, Agria – Volos (GR)P05 The effect of intravesical tarantula cubensis extract on inflamation in interstitial cystitis rat model A. Akdağ, Aydın (TR)P28 Neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer Urologist – R. Catarino, Maia (PT)P07 The possible role of CernitinTM therapy in a model of painful bladder syndrome induced by cyclophosphamide in rats N. Dizeyi, Malmo (SE)14:42 – 14:47 DiscussionP14 Mechanisms of epithelial mesenchymal transition by TGF-ß and LXRs in metastatic prostate cancer E. Bouchareb, Clermont-Ferrand (FR)P19 Zero-ischemic and sutureless partial nephrectomy by using microwave surgical device: Initial results in canine models Urologist – N.H. Nguyen, Ho Chi Minh city (VN)P25 Promising benefits of cold atmospheric plasma-based therapies against bladder cancer L. Fernandes, Coimbra (PT)P13 Artesunate inhibits the progressive growth behavior of docetaxel-resistant prostate cancer cells E. Jüngel, Mainz (DE)P01 The changes of prostatic microvessel density in Sprague-Dawley rats after castration under the effect of estrogen/androgen at different concentrations B. Wang, Guiyang (CN)14:59 – 15:04 Discussion15:10 – 15:50 Session 2: Mechanisms of Tumor Progression and Therapy Resistance Chairs C. Jeronimo, Porto (PT) J. Ceraline, Illkirch (FR)15:10 – 15:30 Oncometabolites: OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation H. Klocker, Innsbruck (AT)15:30 – 15:50 Cancer’s nerves H. Hondermarck, Callaghan (AU)15:50 – 16:50 Presentations selected from abstracts 2 Chairs C. Jeronimo, Porto (PT) J. Ceraline, Illkirch (FR)O11 Cabazitaxel activity and related metabolic changes in RB1 mutated prostate cancer models M. Marin Aguilera, Barcelona (ES)O06 Depletion of ribosomal 2’-O-methylation at 28S-Gm4593 mediated by snoRNASNORD78 reduces the aggressive phenotype of prostate cancer D. Barros-Silva, Porto (PT)O01 miRNA expression profiling in different histological subtypes in penile squamous cell carcinoma H. Ayoubian, Homburg (DE)O10 Small-molecule inhibitors of the Serum Response Factor in combination with enzalutamide: New strategy to treat castrate-resistant prostate cancer M. Prencipe, Dublin (IE)O03 Activation of the aggressive migrational phenotype in prostate cancer cells invading the perineural space Urologist – A. Sachdeva, Manchester (GB)O14 Gene expression and coexpression analysis of the entire bladder cancer clinical stage spectrum R. Stroggilos, Athens (GR)16:50 – 17:10 Journal impact factor, h-index and other metrics: advantage or obstacle of high-quality research16:50 – 17:10 M. Menger, Homburg/Saar (DE)Saturday 9 October 2021
09:15 – 09:20 Welcome Chairs K. Junker, Homburg (DE) G. Van Der Pluijm, Leiden (NL)09:20 – 09:40 Session 3: New Developments in Pathology Chairs A. Vlahou, Athens (GR) M. Colecchia, Milan (IT)09:20 – 09:40 Prostate Cancer Grading beyond Gleason Score Pathologist – G. Van Leenders, Rotterdam (NL)09:40 – 10:40 Presentations selected from abstracts 3 Chairs M. Colecchia, Milan (IT) A. Vlahou, Athens (GR)O04 Digital interferometric polarimetry of the polycrystalline structure for differential diagnosis of prostate tumors Urologist – L. Tryfonyuk, Rivne (UA)O15 Anti-tumour and immune stimulatory effects in bladder cancer of oncolytic reoviruses R124 and mutant jin-3 G. Van Der Horst, Leiden (NL)O12 IFNγ-mediated stimulation of PD-L1 expression on extracellular vesicles from renal cell carcinoma cell lines and their effects on CD8+ T cells G. Jaschkowitz, Homburg/Saar (DE)O13 CD39 and CD73 expression on T cells and tumor cells in bladder cancer Urologist – F. Teixeira Gabriel Furriel, Coimbra (PT)O08 A survey of current trends in urinary extracellular vesicle research E.S. Martens-Uzunova, Rotterdam (NL)O05 The role of LncRNA NAALADL2-AS2 in the development of castration resistant prostate cancer L.N. Groen, Nijmegen (NL)11:00 – 12:05 Session 4: Novel immunotherapic approaches and treatment combinations Chairs I. Heidegger, Innsbruck (AT) A. Masson-Lecomte, Paris (FR)11:00 – 11:20 Promising strategies in immune-oncology N. van Montfoort, ()11:20 – 11:44 Combination therapies in renal carcinoma: Synergism or “just” addition? K. Junker, Homburg (DE) E. Nossner, Munich (DE)11:44 – 12:05 Panel Discussion Panel K. Junker, Homburg (DE) E. Nossner, Munich (DE) N. van Montfoort, Leiden (NL) I. Heidegger, Innsbruck (AT) A. Masson-Lecomte, Paris (FR)12:30 – 13:30 Poster Session 2 – Chairs Urologist – J. Linxweiler, Homburg/saar (DE) E.S. Martens-Uzunova, Rotterdam (NL)P21 Increased expression of Cyclin D 1 as a biomarker in transitional cell carcinoma: A noninvasive approachP10 Interim results from a multicentre clinical trial evaluating a drop-in gamma probe for sentinel lymph node dissection in prostate cancer – C. Solà Marqués, Barcelona (ES)P17 PD-L1 expression on extracellular vesicles in renal cell carcinoma patients Urologist – P. Zeuschner, Homburg (DE)P02 Genome-wide compound heterozygote analysis highlights DPY19L2 alleles in a non-consanguineous Spanish family with a complete form of globozoospermia – L. Bossini-Castillo, Granada (ES)P11 Development of Intraoperative Complications Assessment and Reporting with Universal Standards (ICARUS) criteria for reporting adverse events during surgical procedures and evaluating their impact on the post-operative course – T. Sholklapper, Baltimore (US)12:45 – 12:50 DiscussionP23 Specific miRNA patterns characterize the invasion capability of pT1G3 tumors of the bladder – S. Rau, Homburg/Saar (DE)P06 Could the soluble form of VEGFR1 be used as a biomarker and therapeutic target for BPS/IC? Urologist – P. Abreu-Mendes, Figueira da Foz (PT)P29 Immunological status of bladder cancer patients based on urine leukocyte composition at radical cystectomy – O. Rodriguez Faba, Barcelona (ES)P15 Pathological correlation between prostate biopsies and the radical prostatectomy specimen: A review of 30 cases Urologist – S. A Aboubakry, Nouakchott (MR)P03 The potential use of medical grade Manuka honey in the treatment of interstitial cystitis/bladder pain syndrome – M. Yusuh, Southampton (GB)13:02 – 13:07 DiscussionP18 Tumor-specific proteins on extracellular vesicles as potential biomarkers in renal cell carcinoma – D. Himbert, Homburg (DE)P04 Could early in life stressful events induce a specific bladder pain phenotype inadult female mice? Urologist – P. Abreu-Mendes, Figueira da Foz (PT)P26 A large pilot study on the diagnostic performance of electronic nose in detectingBladder Cancer13:13 – 13:18 Discussion13:30 – 13:40 Wrap-up, announcements and closure of the meeting – Chair K. Junker, Homburg (DE)